Subscribe To Our Free Newsletter |
Aurobindo hits 52-week high; zooms 63% from Feb low on improved performance
Analysts believe Aurobindo has multiple growth drivers in place with investments in vaccines, injectables, biosimilars and PLI, which are expected to be reflected from FY24